Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Authors
Visani, GMilligan, Donald W
Leoni, F
Chang, James
Kelsey, S
Marcus, R
Powles, R
Schey, S
Covelli, A
Isidori, A
Litchman, M
Piccaluga, P P
Mayer, H
Malagola, M
Pfister, C
Affiliation
Istituto di Ematologia e Oncologia Medica L & A Seragnoli, Università degli Studi di Bologna, Azienda Ospedaliera Policlinico Sant'Orsola-Malpighi, Italy.Issue Date
2001-05